Our research with the ADA shows that people with diabetes are much worse off under the COVID-19 pandemic, compared to the nation as a whole.
This survey explores the impact of COVID-19 on diabetes management, revealing high concern, precautionary steps, and changes in work and daily routines.
We surveyed panel members about the FDA advisory on Provention Bio’s teplizumab to delay type 1 diabetes—discover their top concerns and expected impact.
